Journal Specialty Index
Haematology
| Topic | Issue |
| A Patient With Myelodysplastic Syndrome With Ring Sideroblasts and SFB31 Mutations Achieved Transfusion Independence on Luspatercept, a First-In-Class Erythroid Maturation Agent | SEPTEMBER 2025 ‧ VOL. 17 ‧ NO. 8 |
| Salvage Treatment for Hodgkin Lymphoma | SEPTEMBER 2025 ‧ VOL. 17 ‧ NO. 8 |
| Systemic Immunoglobulin Light Chain Amyloidosis and Its Management – Efficacy and Safety Profile | SEPTEMBER 2025 ‧ VOL. 17 ‧ NO. 8 |
| Update on the Novel Treatment of Paroxysmal Nocturnal Haemoglobinuria | SEPTEMBER 2025 ‧ VOL. 17 ‧ NO. 8 |
| Case Report: First Case of Use of Elranatamab (Elrexfio), an Anti-BCMA Bispecific T-cell Engager Antibody for Refractory Myeloma in Hong Kong | NOVEMBER 2024 ‧ VOL. 16 ‧ NO. 11 |
| Bispecific Antibodies for the Treatment of Lymphomas and Multiple Myeloma | NOVEMBER 2024 ‧ VOL. 16 ‧ NO. 11 |
| Precision Guided Missiles Instead of Carpet Bombing: Antibody–Drug Conjugates in Haematological Malignancies | NOVEMBER 2024 ‧ VOL. 16 ‧ NO. 11 |
| CAR-T Cell Therapy: A Paradigm Shift in the Treatment of Haematological Malignancies | NOVEMBER 2024 ‧ VOL. 16 ‧ NO. 11 |
| Safety of Blood Supply in Hong Kong | OCTOBER 2023 (2) ‧ VOL. 15 ‧ NO. 9 |
| Iron-Restricted Erythropoiesis and Treatment With Intravenous Iron | OCTOBER 2023 (2) ‧ VOL. 15 ‧ NO. 9 |
| Allogeneic Haematopoietic Stem Cell Transplantation | OCTOBER 2023 (2) ‧ VOL. 15 ‧ NO. 9 |
| A Review on the Role of Stereotactic Body Radiation Therapy in Hepatocellular Carcinoma | MAY 2023 ‧ VOL. 15 ‧ NO. 3 |
| Update on the Diagnosis and Treatment of Castleman Disease | OCTOBER 2022 ‧ VOL. 14 ‧ NO. 9 |
| An Oral Selective Inhibitor of Exportin 1-Mediated Nuclear Export: Another FDA-Approved New Drug for Multiple Myeloma | OCTOBER 2022 ‧ VOL. 14 ‧ NO. 9 |
| Evolution of Treatment of Acute Myeloid Leukaemia in the Past 50 Years | OCTOBER 2022 ‧ VOL. 14 ‧ NO. 9 |
| Update on the Use of Direct Oral Anticoagulants in the Treatment of Cancer-Associated Thrombosis | SEPTEMBER 2021 ‧ VOL. 13 ‧ NO. 7 |
| Coronavirus Vaccination in Haematological Patients in Hong Kong: The Knowns and Unknowns | SEPTEMBER 2021 ‧ VOL. 13 ‧ NO. 7 |
| Coronavirus Vaccination in Haematological Patients in Hong Kong: The Knowns and Unknowns | SEPTEMBER 2021 ‧ VOL. 13 ‧ NO. 7 |
| Update on the Treatment Strategies for Follicular Lymphoma | SEPTEMBER 2020 ‧ VOL. 12 ‧ NO. 8 |
| Haematological Manifestations of COVID-19 | SEPTEMBER 2020 ‧ VOL. 12 ‧ NO. 8 |
| More Anti-Myeloma Agents in 2019/2020 | SEPTEMBER 2020 ‧ VOL. 12 ‧ NO. 8 |
| Cancer-Associated Thrombosis Treatment Decision Pathway | JANUARY 2020 ‧ VOL. 12 ‧ NO. 1 |
| Myeloma: No Pain, More Gain | NOVEMBER 2019 ‧ VOL. 11 ‧ NO. 8 |
| A Novel Antibody-Drug Conjugate Shows Promise for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma | SEPTEMBER 2019 ‧ VOL. 11 ‧ NO. 6 |
| Novel Targeted Therapies for Acute Myeloid Leukaemia | SEPTEMBER 2019 ‧ VOL. 11 ‧ NO. 6 |
| Recognizing Immune-Mediated Adverse Events in the Treatment of Hodgkin Lymphoma with Checkpoint Inhibitors | SEPTEMBER 2019 ‧ VOL. 11 ‧ NO. 6 |
| Update on the Management of Adult Acute Lymphoblastic Leukaemia | SEPTEMBER 2018 ‧ VOL. 10 ‧ NO. 6 |
| A Step Forward for the Management of Patients with Follicular Lymphoma? | SEPTEMBER 2018 ‧ VOL. 10 ‧ NO. 6 |
| Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia with Novel Targeted Agent (Venetoclax) | SEPTEMBER 2018 ‧ VOL. 10 ‧ NO. 6 |
| Curing Blood Cancers: No More Chemotherapy | NOVEMBER 2017 ‧ VOL. 9 ‧ NO. 7 |
| Rituximab for Subcutaneous Use: New Route of Administration | SEPTEMBER 2017 ‧ VOL. 9 ‧ NO. 6 |
| Good's Syndrome: An Acquired Immunodeficiency Associated with Thymomas | SEPTEMBER 2017 ‧ VOL. 9 ‧ NO. 6 |
| Novel Oral Therapies for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia | SEPTEMBER 2017 ‧ VOL. 9 ‧ NO. 6 |
| Consensus Statements on the Prevention and Management of NOAC-Associated Bleeding in General Practice in Hong Kong | MARCH 2017 ‧ VOL. 9 ‧ NO. 2 |
| Blood Cancers: No More Chemotherapy? | NOVEMBER 2016 ‧ VOL. 8 ‧ NO. 7 |
| Overview of IgG4-related Disease: A Novel Entity | JULY 2016 ‧ VOL. 8 ‧ NO. 5 |
| Hodgkin Lymphoma and Use of Brentuximab Vedotin in its Treatment | JANUARY 2016 ‧ VOL. 8 ‧ NO. 1 |
| Lymphoma: New Age, New Drugs, New Survival | NOVEMBER 2015 ‧ VOL. 7 ‧ NO. 6 |
| Update in the Management of Chronic Lymphocytic Leukaemia (CLL) | MAY 2015 ‧ VOL. 7 ‧ NO. 3 |
| Improving Outcome and Quality of Life in Haematological Malignancies in the Elderly | NOVEMBER 2014 ‧ VOL. 6 ‧ NO. 6 |
| Update in the Management of Mantle Cell Lymphoma | JUNE 2014 ‧ VOL. 6 ‧ NO. 3 |
| Bendamustine: The Gift from Behind the Iron Curtain | JANUARY 2014 ‧ VOL. 6 ‧ NO. 1 |
| Update on the Treatment of Chronic Myeloid Leukaemia | JANUARY 2014 ‧ VOL. 6 ‧ NO. 1 |
| Perioperative Management of Patients on Novel Oral Anticoagulants | JANUARY 2014 ‧ VOL. 6 ‧ NO. 1 |
| Supportive Care in Haematological Malignancies | DECEMBER 2013 ‧ VOL. 5 ‧ NO. 7 |
| Updates in Lymphoplasmacytic Lymphoma and Waldenstrom's Macroglobulinemia | MAY 2013 ‧ VOL. 5 ‧ NO. 3 |
| Young Woman With Deep Vein Thrombosis | NOVEMBER 2012 ‧ VOL. 4 ‧ NO. 6 |
| Update in the Management of Indolent Lymphoma | NOVEMBER 2011 ‧ VOL. 3 ‧ NO. 6 |
| Treatment Options for Patients With Immune Thrombocytopenia | MAY 2010 ‧ VOL. 2 ‧ NO. 3 |
| Update on Management of Myelodysplastic Syndromes | APRIL 2009 ‧ VOL. 1 ‧ NO. 2 |



